



## Tilman Gerlach

### **Kontakt**

Tilman Gerlach

### **Bereiche**

Gastroenterologie | Hepatologie

## Publikationen (48)

Sulz M, Gerlach T. Autoimmunhepatitis – So diagnostizieren und behandeln Sie richtig. Hausarztpraxis 2013;10–14.

Sulz M, Gerlach T. [Autoimmune hepatitis]. Ther Umsch 2011; 68:189–94.

Heeg M, Spannagl M, Kauke T, Horster S, Schraut W, Raziourrouh B, Gerlach T, Jung M, Zachoval R, Grüner N, Ulsenheimer A, Diepolder H. FOXP3 expression in hepatitis C virus-specific CD4+ T cells during acute hepatitis C. Gastroenterology 2009; 137:1280–8.e1–6.

Berg T, Sarrazin C, Neumann K, Zankel M, Balk H, Buggisch P, Spengler U, Gerlach T, Hinrichsen H, Rasenack J, Möller B, Klinker H, Teuber G, Weich V, Zeuzem S. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology (Baltimore, Md.) 2009; 50:369–77.

Dintsios C, Haverkamp A, Wiegand J, Gerlach T, Wedemeyer H, Pape G, Manns M, Krauth C. Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany. European journal of gastroenterology & hepatology 2009

Santantonio T, Wiegand J, Gerlach T. Acute hepatitis C: current status and remaining challenges. Journal of hepatology 2008; 49:625–33.

Johansen P, Bot A, Speck R, Gerlach T, Mullhaupt B, Senti G, Lang K, Manolova V, Smith K, Der-Sarkissian A, Qiu Z, Rettig L, Storni T, Kündig T. Antigen kinetics determines immune reactivity. Proceedings of the National Academy of Sciences of the United States of America 2008; 105:5189–94.

Wildi S, Gubler C, Hany T, Petrowsky H, Clavien P, Jochum W, Gerlach T, Fried M, Mullhaupt B. Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT. Journal of clinical ultrasound : JCU 2008; 36:20–6.

Mullhaupt B, Dimitroulis D, Gerlach T, Clavien P. Hot topics in liver transplantation: organ allocation--extended criteria donor--living donor liver transplantation. Journal of hepatology 2008; 48 Suppl 1:S58–67.

Kronenberger B, Hopf U, Pape G, Wursthorn K, Nasser S, Goeser T, Spengler U, Buggisch P, Gerlach T, Hinrichsen H, Herrmann E, Berg T, Zeuzem S. Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. European journal of gastroenterology & hepatology 2007; 19:639–46.

Goetze O, Selzner N, Fruehauf H, Fried M, Gerlach T, Mullhaupt B. <sup>13</sup>C-methacetin breath test as a quantitative liver function test in patients with chronic hepatitis C infection: continuous automatic molecular correlation spectroscopy compared to isotopic ratio mass spectrometry. Alimentary pharmacology & therapeutics 2007; 26:305–11.

Gruener N, Gerlach T, Ulsenheimer A, Diepolder H, Wierenga E, Zachoval R, Heeg M, Pape G, Jung M. Characterization of sequence variations in immunodominant regions of the HBV-nucleocapsid protein as a prerequisite for the development of an epitope-based vaccine. Vaccine 2007; 25:4960–6.

Lucas M, Santantonio T, Fidler S, Thimme R, Haberstroh A, Baumert T, Klenerman P, Diepolder H, Nitschko H, Obermeier M, Phillips R, Scriba T, Semmo N, Day C, Weber J, Schraut W, Pape G, Zachoval R, Ulsenheimer A, Pfafferot K, Heeg M, Gaudieri S, Grüner N, Rauch A, Gerlach T, Jung M. Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. *PLoS one* 2007; 2:e649.

Ulsenheimer A, Diepolder H, Wucherpfennig K, Pape G, Loughry A, Gruener N, Gerlach T, Seth N, Lucas M, Klenerman P. Transient immunological control during acute hepatitis C virus infection: ex vivo analysis of helper T-cell responses. *Journal of viral hepatitis* 2006; 13:708-14.

Berg T, Alshuth U, Martus P, Spengler U, Klinker H, Kallinowski B, Schmidt W, Pape G, Rasenack J, Goeser T, Buggisch P, Gerlach T, Heintges T, Sarrazin C, Nasser S, von Wagner M, Zeuzem S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. *Gastroenterology* 2006; 130:1086-97.

Gerlach T, Pape G, Zachoval R, Vogler A, Zahn R, Witter K, Scholz S, Heeg M, Schirren C, Schraut W, Jung M, Grüner N, Ulsenheimer A, Diepolder H. Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins. *Journal of virology* 2005; 79:12425-33.

Backmund M, Reimer J, Meyer K, Gerlach T, Zachoval R. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2005; 40 Suppl 5:S330-5.

Ulsenheimer A, Pape G, Zachoval R, Schirren C, Heeg M, Schraut W, Santantonio T, Backmund M, Wächtler M, Gruener N, Jung M, Gerlach T, Diepolder H. Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. *Hepatology (Baltimore, Md.)* 2005; 41:643-51.

Gruener N, Pape G, Schauer R, Baretton G, Diepolder H, Zachoval R, Gerlach T, Ulsenheimer A, Jung M, Schirren C. Analysis of a successful HCV-specific CD8+ T cell response in patients with recurrent HCV-infection after orthotopic liver transplantation. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society* 2004; 10:1487-96.

Steinmann D, Blum H, Liang T, Inchauspé G, Patel A, Maertens G, Jacobs D, Depla E, Pape G, Gerlach T, Adah M, Schürmann P, Gissler B, Barth H, Baumert T. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. *Journal of virology* 2004; 78:9030-40.

Berg T, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Zachoval R, Zeuzem S. Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?. *Hepatology (Baltimore, Md.)* 2004; 39:1456-7; author reply 1457-8.

Schirren C, Pape G, Nitschko H, Rau H, Schraut W, Baretton G, Diepolder H, Gruener N, Ulsenheimer A, Gerlach T, Zachoval R, Jung M. Antiviral treatment of recurrent hepatitis C virus (HCV) infection after liver transplantation: association of a strong, multispecific, and long-lasting CD4+ T cell response with HCV-elimination. *Journal of hepatology* 2003; 39:397-404.

Gerlach T, Backmund M, Wächtler M, Schirren C, Schraut W, Ulsenheimer A, Jung M, Gruener N, Zachoval R, Diepolder H, Pape G. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. *Gastroenterology* 2003; 125:80-8.

Berg T, Hopf U, Pape G, Wursthorn K, Nasser S, Goeser T, Spengler U, Herrmann E, Buggisch P, Gerlach T, Hinrichsen H, Kronenberger B, Zeuzem S. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. *Hepatology (Baltimore, Md.)* 2003; 37:1359-67.

Ulsenheimer A, Gerlach T, Gruener N, Jung M, Schirren C, Schraut W, Zachoval R, Pape G, Diepolder H. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. *Hepatology* (Baltimore, Md.) 2003; 37:1189-98.

Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. *Hepatology* (Baltimore, Md.) 2003; 37:600-9.

Gruener N, Backmund M, Wächtler M, Hoffmann R, Schirren C, Diepolder H, Gerlach T, Ulsenheimer A, Jung M, Pape G. Hepatitis C virus eradication associated with hepatitis B virus superinfection and development of a hepatitis B virus specific T cell response. *Journal of hepatology* 2002; 37:866-9.

Jung M, Zeuzem S, Trojan J, Whitehead E, Birtles E, Bailey J, Page M, Schirren C, Diepolder H, Gerlach T, Schraut W, Zachoval R, Grüner N, Pape G. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. *Vaccine* 2002; 20:3598-612.

Diepolder H, Gruener N, Gerlach T, Jung M, Wierenga E, Pape G. Different levels of T-cell receptor triggering induce distinct functions in hepatitis B and hepatitis C virus-specific human CD4(+) T-cell clones. *Journal of virology* 2001; 75:7803-10.

Gruener N, Pape G, Phillips R, Sullivan J, Walker B, Lauer G, Gerlach T, Diepolder H, Jung M, Lechner F, Klenerman P. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. *Journal of virology* 2001; 75:5550-8.

Schirren C, Rau H, Houghton M, Zachoval R, Gruener N, Gerlach T, Baretton G, Mamin M, Worzfeld T, Jung M, Pape G. Hepatitis C virus-specific CD4+ T cell response after liver transplantation occurs early, is multispecific, compartmentalizes to the liver, and does not correlate with recurrent disease. *The Journal of infectious diseases* 2001; 183:1187-94.

Schirren C, Jung M, Gerlach T, Worzfeld T, Baretton G, Mamin M, Hubert Gruener N, Houghton M, Pape G. Liver-derived hepatitis C virus (HCV)-specific CD4(+) T cells recognize multiple HCV epitopes and produce interferon gamma. *Hepatology* (Baltimore, Md.) 2000; 32:597-603.

Cucchiari M, Pape G, Reichen J, Santantonio T, Grüner N, Gerlach T, Diepolder H, Grabscheid B, Kammer A, Cerny A. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. *Cellular immunology* 2000; 203:111-23.

Grüner N, Cerny A, Cucchiari M, Santantonio T, Zachoval R, Hoffmann R, Schraut W, Schirren C, Diepolder H, Jung M, Gerlach T, Pape G. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. *The Journal of infectious diseases* 2000; 181:1528-36.

Schirren C, Zachoval R, Diepolder H, Gerlach T, Gruener N, Baretton G, Mamin M, Worzfeld T, Jung M, Pape G. Cytokine profile of liver- and blood-derived nonspecific T cells after liver transplantation: T helper cells type 1/0 lymphokines dominate in recurrent hepatitis C virus infection and rejection. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society* 2000; 6:222-8.

Gerlach T, Santantonio T, Schirren C, Hoffmann R, Zachoval R, Schraut W, Gruener N, Jung M, Diepolder H, Pape G. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. *Gastroenterology* 1999; 117:933-41.

Jung M, Wächtler M, Santantonio T, Hoffmann R, Zachoval R, Grüner N, Schraut W, Gruber R, Diepolder H, Gerlach T, Hartmann B, Pape G. Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. *Virology* 1999; 261:165-72.

Pape G, Gerlach T, Diepolder H, Grüner N, Jung M, Santantonio T. Role of the specific T-cell response for clearance and control of hepatitis C virus. *Journal of viral hepatitis* 1999; 6 Suppl 1:36-40.

Diepolder H, Ries G, Jung M, Schlicht H, Gerlach T, Grüner N, Caselmann W, Pape G. Differential antigen-processing pathways of the hepatitis B virus e and core proteins. *Gastroenterology* 1999; 116:650-7.

Diepolder H, Scholz S, Schirren C, Hoffmann R, Zachoval R, Grüner N, Gerlach T, Schraut W, Keller E, Jung M, Pape G. A vigorous virus-specific CD4+ T cell response may contribute to the association of HLA-DR13 with viral clearance in hepatitis B. *Clinical and experimental immunology* 1998; 113:244-51.

Diepolder H, Hoffmann R, Gerlach T, Zachoval R, Jung M, Pape G. Immunopathogenesis of HCV infection. *Current studies in hematology and blood transfusion* 1998:135-51.

Krombach F, Münzing S, Allmeling A, Gerlach T, Behr J, Dörger M. Cell size of alveolar macrophages: an interspecies comparison. *Environmental health perspectives* 1997; 105 Suppl 5:1261-3.

Diepolder H, Sette A, Southwood S, Houghton M, Santantonio T, Scholz S, Wierenga E, Jung M, Hoffmann R, Zachoval R, Gerlach T, Pape G. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. *Journal of virology* 1997; 71:6011-9.

Diepolder H, Riethmüller G, Heavner G, Scholz S, Gerlach T, Zachoval R, Hoffmann R, Wierenga E, Jung M, Pape G. Anergic TH1 clones specific for hepatitis B virus (HBV) core peptides are inhibitory to other HBV core-specific CD4+ T cells in vitro. *Journal of virology* 1996; 70:7540-8.

Diepolder H, Zachoval R, Hoffmann R, Jung M, Gerlach T, Pape G. The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C. *Journal of molecular medicine (Berlin, Germany)* 1996; 74:583-8.

Gülberg V, Wagershauser T, Beuers U, Gerlach T, Gerbes A. [46-year-old patient with recurrent hematemesis]. *Der Internist* 1996; 37:515-7.

Krombach F, Gerlach T, Padovan C, Burges A, Behr J, Beinert T, Vogelmeier C. Characterization and quantification of alveolar monocyte-like cells in human chronic inflammatory lung disease. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 1996; 9:984-91.

Padovan C, Behr J, Allmeling A, Gerlach T, Vogelmeier C, Krombach F. Immunophenotyping of lymphocyte subsets in bronchoalveolar lavage fluid. Comparison of flow cytometric and immunocytochemical techniques. *Journal of immunological methods* 1992; 147:27-32.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)